4.0 Article

Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis

Journal

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
Volume 19, Issue 1, Pages 22-27

Publisher

SAGE PUBLICATIONS INC
DOI: 10.2310/7750.2014.13151

Keywords

-

Categories

Funding

  1. AbbVie
  2. Novartis
  3. Actelion
  4. Amgen
  5. Astellas
  6. Bio-K
  7. Celgene
  8. Galderma
  9. Janssen
  10. LEO Pharma
  11. Merck/Schering
  12. Pfizer
  13. Roche
  14. Valeant
  15. Abbott
  16. Centocor
  17. Isotechnika
  18. Lilly
  19. Merck
  20. Ortho Biotech
  21. Wyeth
  22. Eli Lilly

Ask authors/readers for more resources

Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. Results: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). Conclusion: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available